TASTE MASKING BY HOT MELT EXTRUSION WITHOUT LOSS OF BIOAVAILABILITY FOR PEDIATRICS
PALATABLE FLEXIBLE PEDIATRIC DOSAGE FORM
Objective: The aim of present work was to develop a platform technology for the pediatric dosage form to mask the bitter taste of Furosemide (FUR) and prepare a flexible solid oral dosage form.
Methods: Excipient compatibility study was carried out by using Fourier-transform infrared spectroscopy (FTIR). Taste masking was done by hot melt extrusion (HME) technology. Eudragit EPO and Soluplus were used as a taste masking and solubilizing polymers respectively. The prepared solid dispersion and tablets were evaluated for their physicochemical parameters such as hardness, friability, disintegration, in vitro drug release.
Results: Experimental data revealed that physical integrity, brittleness of granules, conversion of a drug in amorphous form was improved by combining Eudragit EPO with Soluplus. Plasticizer helped to complete HME at 80 °C. Less than 10% drug release in pH 6.8 medium revealed that release would be extremely limited in the saliva and thus avoiding bitterness. Animal study data revealed that bioavailability has been increased by 30%. Differential scanning calorimetry (DSC) and x-ray diffraction (XRD) tests confirmed the existence of molecularly dispersed drug. Fourier-transform infrared spectroscopy (FTIR) confirmed the unchanged functional groups of FUR after HME processing.
Conclusion: Proposed platform technology masked the bitter taste and enhanced the bioavailability of FUR in D: P ratio of 1:2.
2. Debra LP. Pediatric formulation development: challenges and opportunities from an industry perspective. Worldwide pharmaceutical sciences. US FDA. Presentation to the pediatric oncology subcommittee of the oncologic drugs advisory committee; 2009.
3. Formulations of choice for the pediatric population. Reflection paper by European Medicines Agency. Pre-authorization Evaluation of Medicines for Human Use. Committee for Medicinal Products for Human Use (CHMP); 2006.
4. Ghulam M, Shujaat AK, Muhammad NH, Izhar H. Comparative evaluation of various solubility enhancement strategies for furosemide. Pak J Pharm Sci 2014;27:963-73.
5. Granero GE, Longhi MR, Mora MJ, Junginger HE, Midha KK, Shah VP. Biowaiver monographs for immediate release solid oral dosage forms: furosemide. J Pharm Sci 2010;6:2544-56.
6. Product information leaflet. Lasix (Furosemide) tablets 20, 40 and 80 mg. By Sanofi Aventis. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/016273s066lbl.pdf. [Last accessed on 05 Mar 2019].
7. Rafik K. Prodrugs for masking the bitter taste of drugs. In: Li DS. editor. Application of nanotechnology in drug delivery. 1st ed; 2014. p. 399-445.
8. Zainab EJ. Formulation and evaluation of furosemide liquisolid compact. Int J Appl Pharm 2017;9:39-48.
9. Mohammed M, Ali N. Continuous manufacturing via hot-melt extrusion and scale up: regulatory matters. Drug Discovery Today 2017;22:340-51.
10. Suniket F, Sarah R. Taste-masking, pharmaceutical taste-masking technologies. Drug Dev Delivery 2015;15:64-8.
11. Hemlata P, Roshan VT, Michael AR. Hot-melt extrusion: from theory to application in pharmaceutical formulation. AAPS PharmSciTech 2016;17:20-42.
12. Jia L, Feng C, Can Z, Qineng P. Use of polymer combinations in the preparation of solid dispersions of a thermally unstable drug by hot-melt extrusion. Acta Pharm Sin B 2013;4:263–72.
13. Kolter K, Karl M, Gryczke A. Hot melt extrusion with BASF pharma polymers. Extrusion Compendium. 2nd ed; 2012.
14. Kamlesh M, Rahul J, Mandar M, Subhashis C. Exploring Eudragit EPO for taste masking of bitter drugs using hot melt extrusion. AAPS Annual Meeting and Exposition. Poster No. W4205; 2011.
15. Chang RK, Peng Y, Trivedi N, Shukla AJ. Polymethacrylates. In: Raymond CR, Paul JS, Marian EQ. editors. Handbook of Pharmaceutical Excipients. 6th ed. London: Pharmaceutical Press; 2009. p. 525-33.
16. Keating AV, Soto J, Tuleu C, Forbes C, Zhao M, Craig D. Solid state characterization and taste masking efficiency evaluation of polymer-based extrudates of isoniazid for pediatric administration. Int J Pharm 2018;536:536-46.
17. Maniruzzaman M, Boateng JS, Chowdhry BZ, Snowden MJ, Douroumis D. A review on taste masking of bitter APIs: hot melt extrusion (HME) evaluation. Drug Dev Ind Pharm 2014;2:145-56.
18. Ghebremeskel AN, Vemavarapu C, Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: the selection of polymer–surfactant combinations using solubility parameters and testing the processability. Int J Pharm 2007;328:119–29.
19. Sandeep K, Mohanvarma M, Veerabhadhraswamy P. Oral lipid-based drug delivery systems-an overview. Acta Pharm Sin B 2013;6:361-72.
20. Deshmukh V, Mulik S, Deshmukh T, Kasat K. Solubility enhancement of efavirenz hydrochloride by hot melt technique. Cur Pharma Res 2011;4:320-36.
21. Edgar R, Ketaki P, Firouz A. Prediction of API solubility in solid solutions using modified solubility parameters, film casting and melt extrusion. AAPS Annual Meeting Exposition, Poster No. W4313; 2011.
22. Tablet Friability. Chapter 1216. United State Pharmacopoeia 39 (USP 39)/National Formulary 34 (NF 34); 2016. p. 1609.
23. Fell JT, Newton JM. Determination of tablet strength by diametral compression test. J Pharm Sci 1970;59:688–91.
24. Disintegration. Chapter 701. United State Pharmacopoeia 39 (USP 39)/National Formulary 34 (NF 34); 2016. p. 537.
25. Dissolution. Chapter 711. In: United State Pharmacopoeia 39 (USP 39)/National Formulary 34 (NF 34); 2016. p. 540.
26. Stability testing of new drug substances and products. ICH harmonized tripartite guideline. International Conference on Harmonization (ICH) of technical requirements for registration of pharmaceuticals for human use; 2003:Q1A(R2). p. 1-18.
27. Furosemide tablets monograph. United States Pharmacopoeia 39 (USP 39)/National Formulary 34 (NF 34); 2009. p. 4061.
28. Dejan D, Soluplus. In: Thomas R. editor. Solubility enhancement with BASF pharma polymer. Solubilizer Compendium; 2011. p. 67-8.
29. Dan W. Excipients for formulation success, cover story. Pharm Technol 2016;40:22-7.
30. Farha AS, Shubhrajit M. Formulation and evaluation of tenofovir disoproxil fumarate immediate-release tablets. Int J Inno Pharm Sci Res 2013;2:252-65.
31. Shin Oh I, Lee Y, Choi H, Choi J. Enhanced dissolution of furosemide by co-precipitating or co-grinding with crospovidone. Int J Pharm 1998;175:17–24.
32. Tablets general monograph. In: British Pharmacopoeia. Volume III; 2017. p.73-6.
33. Elaine NM. The digestive system. In: Human anatomy and physiology. 6th ed; 2006. p. 881.
34. Guideline on a declaration of storage conditions: A: In the product information of medicinal products, B: for active substances. European Medicines Agency. Committee for medicinal products for human use (CHMP); 2003. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003468.pdf. [Last accessed on 10 Jan 2017].
35. Sandeep K, Arun N. Formulation, optimization and in vitro evaluation of gastroretentive mucoadhesive microspheres of furosemide. Int J Appl Pharm 2016;7:392-8.
This work is licensed under a Creative Commons Attribution 4.0 International License.